Tumor Biology

, Volume 37, Issue 7, pp 9151–9156 | Cite as

Expression of Pim-3 in colorectal cancer and its relationship with prognosis

  • Zhongguo Zhou
  • Rongxin Zhang
  • Ruojing Wang
  • Yaojun Zhang
  • Li Xu
  • Jinbin Chen
  • Jie Zhang
  • Zhongxi Huang
  • Minshan Chen
  • Zhizhong Pan
Original Article

Abstract

There is increasing evidence suggesting that the establishment of Pim-3 is involved in tumorigenesis. This study aimed to investigate the expression and clinicopathological significance of Pim-3 in colorectal cancer (CRC). Clinical pathology data were collected from 410 CRC patients who received radical resection and were pathologically confirmed at the Sun Yat-Sen University Cancer Center between October 2002 and December 2008. We compared the expression Pim-3 in the primary focus and liver metastasis and investigated the correlations with other clinical-pathological factors. Multivariate analysis showed that perioperative blood transfusion, local invasion, lymph node and liver metastasis, and Pim-3 expression were independent prognostic factors. The expression of Pim-3 in CRC was higher than that in normal tissues. Patients with positive expression had significant decreases in 5-year survival. Pim-3 expression showed a positive correlation with tumor cell differentiation, local infiltration, and lymph node and liver metastasis. In conclusion, Pim-3 might serve as a novel target and prognosis factor for colorectal cancer.

Keywords

Pim-3 Colorectal cancer Metastasis Prognosis 

Notes

Acknowledgments

This study was supported by grants from the Guangdong Academy of Medical Science and Technology Research Foundation (No. B2012137).

Compliance with ethical standards

Conflicts of interest

None

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37:141–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11:23–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The Pim family of serine/threonine kinases in cancer. Med Res Rev. 2014;34:136–59.CrossRefPubMedGoogle Scholar
  5. 5.
    Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 2011;102:1437–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Peng YH, Li JJ, Xie FW, Chen JF, Yu YH, Ouyang XN, et al. Expression of Pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients. PLoS One. 2013;8, e76693.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Lou L, Wang Y, Cui J, Yan X, Xue L, Li Y. Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:5029–36.CrossRefGoogle Scholar
  11. 11.
    Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, et al. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget. 2015;6:14440–55.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Quan J, Zhou L, Qu J. Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis. Cell Mol Biol. 2015;61:42–50.PubMedGoogle Scholar
  13. 13.
    Zhuang H, Zhao MY, Hei KW, Yang BC, Sun L, Du X, et al. Aberrant expression of Pim-3 promotes proliferation and migration of ovarian cancer cells. Asian Pac J Cancer Prev. 2015;16:3325–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Li YY, Mukaida N. Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression. World J Gastroenterol. 2014;20:9392–404.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Liu LH, Lai QN, Chen JY, Zhang JX, Cheng B. Overexpression of Pim-3 and protective role in lipopolysaccharide-stimulated hepatic stellate cells. World J Gastroenterol. 2015;21:8858–67.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ul-Haq Z, Gul S, Usmani S, Wadood A, Khan W. Binding site identification and role of permanent water molecule of Pim-3 kinase: a molecular dynamics study. J Mol Graph Model. 2015;62:276–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leukemia lymphoma. 2015;1–9.Google Scholar
  18. 18.
    Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. Azd1208, a potent and selective Pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123:905–13.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zhang G, Liu Z, Cui G, Wang X, Yang Z. MicroRNA-486-5p targeting Pim-1 suppresses cell proliferation in breast cancer cells. Tumour Biol. 2014;35:11137–45.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zhongguo Zhou
    • 1
  • Rongxin Zhang
    • 1
  • Ruojing Wang
    • 2
  • Yaojun Zhang
    • 1
  • Li Xu
    • 1
  • Jinbin Chen
    • 1
  • Jie Zhang
    • 1
  • Zhongxi Huang
    • 1
  • Minshan Chen
    • 1
  • Zhizhong Pan
    • 1
  1. 1.State Key Laboratory of Southern China; Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  2. 2.First Affiliated Hospital of Sun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations